Stockscreener 앱 받기
472.35
0.75%
3.50
시간 외 거래:
472.35
전일 마감가:
$468.85
열려 있는:
$467.69
하루 거래량:
729.78K
Relative Volume:
0.46
시가총액:
$121.30B
수익:
$11.10B
순이익/손실:
$-988.90M
주가수익비율:
-120.50
EPS:
-3.92
순현금흐름:
$-1.26B
1주 성능:
+2.82%
1개월 성능:
+3.71%
6개월 성능:
+14.74%
1년 성능:
-3.35%
1일 변동 폭
$467.00
$475.27
1주일 범위
$456.77
$484.56
52주 변동 폭
$377.85
$519.88
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
472.35 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.59 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.75 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
561.28 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.14 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
First-in-Class Non-Opioid Pain Treatment: Vertex's JOURNAVX Clinches Major Healthcare Innovation Award - Stock Titan
Vertex Pharmaceuticals: A Steady Hand in a Volatile Market - AInvest
Vertex Pharmaceuticals Leads Biotech Stocks with 16%+ YTD Increase - AInvest
Why Vertex Pharmaceuticals Continues To Outperfrom (NASDAQ:VRTX) - Seeking Alpha
10 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool
Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval - PMLiVE
Vertex Pharmaceuticals Develops Journavx Targeting Sodium Channels NaV1.8 and NaV1.7 for Non-Opioid Pain Relief - geneonline.com
Vertex Pharmaceuticals Q2 2025 Earnings: A Catalyst for Dominance in Rare Disease Therapeutics - AInvest
Vertex to Announce Second Quarter 2025 Financial Results on August 4th - Yahoo Finance
Cystic Fibrosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma - Barchart.com
RBC Capital Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)? - Yahoo Finance
FDA Approves Suzetrigine by Vertex Pharmaceuticals for Acute Pain Relief in Adults - geneonline.com
China Universal Asset Management Co. Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY - Yahoo Finance
Vertex Pharmaceuticals (NasdaqGS:VRTX) Secures EU Approval for New CF Treatment Access - Yahoo Finance
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU - Stocktwits
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Vertex Pharmaceuticals Slips to 247th in Trading Volume Despite FDA Approval and Innovation Award - AInvest
Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug - Insider Monkey
Vertex Pharmaceuticals Unusual Options Activity - Benzinga
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Yahoo Finance
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market - Nasdaq
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
10 Biotech Stocks Screaming a Buy - Insider Monkey
Vertex Pharmaceuticals (VRTX) Soared as Investors Back Strategic Initiatives - Insider Monkey
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Price Target Slightly Reduced by R - GuruFocus
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 10 Analysts - Nasdaq
Vertex Pharmaceuticals price target lowered to $420 from $423 at RBC Capital - TipRanks
Vertex Pharmaceuticals (VRTX) Price Target Lowered Amid Concerns - GuruFocus
Vertex Pharmaceuticals (VRTX) Price Target Lowered Amid Concerns | VRTX Stock News - GuruFocus
RBC Capital Adjusts PT on Vertex Pharmaceuticals to $420 From $423, Maintains Sector Perform Rating - MarketScreener
Aries Wealth Management Buys New Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Everhart Financial Group Inc. Buys 553 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
CCM Investment Advisers LLC Acquires 5,351 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Opinicus Capital Inc. Invests $397,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Ferguson Wellman Capital Management Inc. Takes $391,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by RMR Wealth Builders - MarketBeat
Integrated Advisors Network LLC Has $1.05 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Optas LLC Has $864,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Brighton Jones LLC Purchases 1,994 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Foster Victor Wealth Advisors LLC Sells 1,664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Massachusetts Wealth Management Makes New Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Yousif Capital Management LLC Sells 664 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Simplicity Wealth LLC Has $630,000 Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Redhawk Wealth Advisors Inc. Cuts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansion - Investing.com
Compagnie Lombard Odier SCmA Raises Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Simon Quick Advisors LLC Has $1.42 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
SG Americas Securities LLC Purchases 17,502 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
1.67%
자본화:
|
볼륨(24시간):